Centers of Excellence in Specialty Tops SPT Week in Review

Top news of the week from Specialty Pharmacy Times.

5. First Short-Course Oral Therapy Approved for Relapsing Forms of MS

Cladribine (Mavenclad, EMD Serono) is the first oral multiple sclerosis drug to demonstrate 2 years of proven efficacy with a maximum of 20 days of treatment. Read more.

4. Gilteritinib Prolongs Survival in Patients with FLT3-Mutated AML

Gilteritinib (Xospata) was superior to standard chemotherapy in improving overall survival in patients with acute myeloid leukemia. Read more.

3. FDA Approves Novel Intravenous Immune Globulin

Immune Globulin Intravenous, Human — slra 10% Liquid (Asceniv) is indicated for use in the treatment of primary humoral immunodeficiency disease in adults and adolescents. Read more.

2. Medicaid Coverage of Recommended Lung Cancer Screenings Varies Across States

Although lung cancer screenings are covered at no cost by most insurers, state Medicaid programs are not required to offer coverage for this service. Read more.

1. A Step by Step Guide to Establishing and Maintaining a Special Center of Excellence

Specialty pharmacy can benefit from having definitive a center of excellence model that caters to respective therapies and disease states. Read more.